Guardant360® Liquid CDx
A comprehensive genomic profiling assay used as a companion diagnostic to select patients for targeted therapies across multiple solid tumors.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
Guardant360® Liquid CDx is an in vitro diagnostic test that uses next-generation sequencing to identify genomic alterations in solid tumors. It is approved by the FDA as a companion diagnostic for multiple targeted therapies across tumor types.
Results from this assay help determine whether a patient is eligible for specific therapies based on the genomic profile of their tumor.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Breast Cancer | ESR1 | ESR1 E380, V422del, S463, L469, L536, Y537, and D538 mutations | INLURIYO |
| ESR1 missense mutations between codons 310 and 547 | ORSERDU | ||
| Colorectal Cancer (CRC) | BRAF | V600E | BRAFTOVI + ERBITUX |
| Non-Small Cell Lung Cancer (NSCLC) | EGFR (HER1) | Exon 19 deletions or exon 21 L858R, and T790M | TAGRISSO |
| Exon 20 insertions | RYBREVANT | ||
| ERBB2 (HER2) | Activating Mutations (SNVs And Exon 20 Insertions) | ENHERTU | |
| KRAS | G12C | LUMAKRAS |
Performing lab
Penobscot Drive Lab (05D2070300)
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Order this test
If your organization is connected to Casandra, you can place an electronic order for Guardant360® Liquid CDx directly from your existing workflow.
Order via CasandraCasandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.